Document Detail

Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors.
MedLine Citation:
PMID:  17288877     Owner:  NLM     Status:  MEDLINE    
Lenalidomide is a novel analog of thalidomide with both immunomodulatory and antiangiogenic properties that are more potent than those same properties in the parent compound. Work in several antiangiogenic model systems has provided early evidence of potential mechanisms of its clinical activity. Recent US Food and Drug Administration approval of lenalidomide for patients with deletion 5q myelodysplastic syndromes and advanced multiple myeloma has provided impetus for further evaluation of this agent in solid tumors.
Robert Dreicer
Related Documents :
953997 - The reversible expression of an adult isozyme locus, gdc-1, in tumors of the mouse.
9042207 - Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, a...
20199387 - Stable disease in renal cell carcinoma after using signal transduction inhibitors.
17214327 - Spindle checkpoint protein hmad2 and histone h3 phosphoserine 10 mitosis marker in pedi...
8516227 - Astroblastoma: report of a case with ultrastructural, cell kinetic, and cytogenetic ana...
24768217 - Malignant transformation of a desmoplastic infantile ganglioglioma in an infant carrier...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current oncology reports     Volume:  9     ISSN:  1523-3790     ISO Abbreviation:  Curr Oncol Rep     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-02-09     Completed Date:  2007-04-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888967     Medline TA:  Curr Oncol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  120-3     Citation Subset:  IM    
Department of Solid Tumor Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use*
Immunologic Factors / therapeutic use*
Neoplasms / drug therapy*
Thalidomide / analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Immunologic Factors; 191732-72-6/lenalidomide; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
Next Document:  Contemporary management of tumors of the salivary glands.